NO763776L - - Google Patents

Info

Publication number: NO763776L
Authority: NO; Norway
Prior art keywords: floatate; coagulation; further purification; aqueous; factor
Prior art date: 1975-11-07

Application number

NO763776A

Other languages

English (en)

Norwegian (no)

Inventor

H Schwinn

N Heimburger

Original Assignee

Behringwerke Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1975-11-07

Filing date

1976-11-05

Publication date

1977-05-10

1976-11-05 Application filed by Behringwerke Ag filed Critical Behringwerke Ag

1977-05-10 Publication of NO763776L publication Critical patent/NO763776L/no

Links

108010054218 Factor VIII Proteins 0.000 claims description 32
102000001690 Factor VIII Human genes 0.000 claims description 32
229960000301 factor viii Drugs 0.000 claims description 32
230000000694 effects Effects 0.000 claims description 27
238000000034 method Methods 0.000 claims description 27
239000000243 solution Substances 0.000 claims description 27
210000002381 plasma Anatomy 0.000 claims description 22
230000000603 anti-haemophilic effect Effects 0.000 claims description 21
239000003795 chemical substances by application Substances 0.000 claims description 19
238000000746 purification Methods 0.000 claims description 17
210000002826 placenta Anatomy 0.000 claims description 15
102000004169 proteins and genes Human genes 0.000 claims description 13
108090000623 proteins and genes Proteins 0.000 claims description 13
239000012266 salt solution Substances 0.000 claims description 13
230000015271 coagulation Effects 0.000 claims description 11
238000005345 coagulation Methods 0.000 claims description 11
150000001875 compounds Chemical class 0.000 claims description 10
238000002560 therapeutic procedure Methods 0.000 claims description 9
238000005188 flotation Methods 0.000 claims description 8
238000006467 substitution reaction Methods 0.000 claims description 8
230000002950 deficient Effects 0.000 claims description 7
239000000284 extract Substances 0.000 claims description 7
239000000126 substance Substances 0.000 claims description 7
238000004587 chromatography analysis Methods 0.000 claims description 6
239000002808 molecular sieve Substances 0.000 claims description 6
URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 claims description 6
239000012736 aqueous medium Substances 0.000 claims description 5
239000000084 colloidal system Substances 0.000 claims description 5
238000004519 manufacturing process Methods 0.000 claims description 5
230000001681 protective effect Effects 0.000 claims description 5
230000002378 acidificating effect Effects 0.000 claims description 4
239000008346 aqueous phase Substances 0.000 claims description 4
238000001990 intravenous administration Methods 0.000 claims description 4
239000002904 solvent Substances 0.000 claims description 4
102000015081 Blood Coagulation Factors Human genes 0.000 claims description 3
108010039209 Blood Coagulation Factors Proteins 0.000 claims description 3
239000003114 blood coagulation factor Substances 0.000 claims description 3
229940079593 drug Drugs 0.000 claims description 3
239000003814 drug Substances 0.000 claims description 3
150000002632 lipids Chemical class 0.000 claims description 3
229920001184 polypeptide Polymers 0.000 claims description 3
230000008569 process Effects 0.000 claims description 3
102000004196 processed proteins & peptides Human genes 0.000 claims description 3
108090000765 processed proteins & peptides Proteins 0.000 claims description 3
239000006228 supernatant Substances 0.000 claims description 3
231100000732 tissue residue Toxicity 0.000 claims description 3
239000000969 carrier Substances 0.000 claims description 2
230000009918 complex formation Effects 0.000 claims description 2
229920000831 ionic polymer Polymers 0.000 claims description 2
239000002609 medium Substances 0.000 claims description 2
238000005187 foaming Methods 0.000 claims 1
238000002360 preparation method Methods 0.000 description 23
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 14
235000002639 sodium chloride Nutrition 0.000 description 13
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 12
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
239000000203 mixture Substances 0.000 description 12
238000007792 addition Methods 0.000 description 10
229960004222 factor ix Drugs 0.000 description 10
235000018102 proteins Nutrition 0.000 description 10
239000000047 product Substances 0.000 description 9
150000003839 salts Chemical class 0.000 description 7
102000009027 Albumins Human genes 0.000 description 6
108010088751 Albumins Proteins 0.000 description 6
102100022641 Coagulation factor IX Human genes 0.000 description 6
108010094028 Prothrombin Proteins 0.000 description 6
102100027378 Prothrombin Human genes 0.000 description 6
229920000669 heparin Polymers 0.000 description 6
IOLCXVTUBQKXJR-UHFFFAOYSA-M potassium bromide Chemical compound [K+].[Br-] IOLCXVTUBQKXJR-UHFFFAOYSA-M 0.000 description 6
229940039716 prothrombin Drugs 0.000 description 6
239000011780 sodium chloride Substances 0.000 description 6
108010076282 Factor IX Proteins 0.000 description 5
208000009292 Hemophilia A Diseases 0.000 description 5
102000008100 Human Serum Albumin Human genes 0.000 description 5
108091006905 Human Serum Albumin Proteins 0.000 description 5
238000004140 cleaning Methods 0.000 description 5
238000000605 extraction Methods 0.000 description 5
230000007935 neutral effect Effects 0.000 description 5
235000011121 sodium hydroxide Nutrition 0.000 description 5
201000003542 Factor VIII deficiency Diseases 0.000 description 4
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 4
239000002253 acid Substances 0.000 description 4
238000009835 boiling Methods 0.000 description 4
238000000502 dialysis Methods 0.000 description 4
229960002897 heparin Drugs 0.000 description 4
239000000463 material Substances 0.000 description 4
210000005059 placental tissue Anatomy 0.000 description 4
239000000725 suspension Substances 0.000 description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 3
102100026735 Coagulation factor VIII Human genes 0.000 description 3
101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 3
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
241001465754 Metazoa Species 0.000 description 3
102000007327 Protamines Human genes 0.000 description 3
108010007568 Protamines Proteins 0.000 description 3
108010000499 Thromboplastin Proteins 0.000 description 3
102000002262 Thromboplastin Human genes 0.000 description 3
239000003513 alkali Substances 0.000 description 3
230000023555 blood coagulation Effects 0.000 description 3
150000001720 carbohydrates Chemical class 0.000 description 3
235000014633 carbohydrates Nutrition 0.000 description 3
238000005119 centrifugation Methods 0.000 description 3
230000007812 deficiency Effects 0.000 description 3
238000010790 dilution Methods 0.000 description 3
239000012895 dilution Substances 0.000 description 3
238000010828 elution Methods 0.000 description 3
229940012413 factor vii Drugs 0.000 description 3
150000003904 phospholipids Chemical class 0.000 description 3
230000003248 secreting effect Effects 0.000 description 3
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
239000004215 Carbon black (E152) Substances 0.000 description 2
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
102100023804 Coagulation factor VII Human genes 0.000 description 2
206010010356 Congenital anomaly Diseases 0.000 description 2
108010023321 Factor VII Proteins 0.000 description 2
239000005715 Fructose Substances 0.000 description 2
229930091371 Fructose Natural products 0.000 description 2
RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
102000006395 Globulins Human genes 0.000 description 2
108010044091 Globulins Proteins 0.000 description 2
208000031220 Hemophilia Diseases 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
230000009471 action Effects 0.000 description 2
239000011149 active material Substances 0.000 description 2
239000000654 additive Substances 0.000 description 2
239000006286 aqueous extract Substances 0.000 description 2
TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 2
239000002585 base Substances 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
239000012141 concentrate Substances 0.000 description 2
ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 2
239000012153 distilled water Substances 0.000 description 2
238000005194 fractionation Methods 0.000 description 2
238000004108 freeze drying Methods 0.000 description 2
208000009429 hemophilia B Diseases 0.000 description 2
230000000027 hemostyptic effect Effects 0.000 description 2
ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 2
229960001008 heparin sodium Drugs 0.000 description 2
229930195733 hydrocarbon Natural products 0.000 description 2
150000002430 hydrocarbons Chemical class 0.000 description 2
238000002156 mixing Methods 0.000 description 2
230000036961 partial effect Effects 0.000 description 2
239000003208 petroleum Substances 0.000 description 2
230000003169 placental effect Effects 0.000 description 2
229920000447 polyanionic polymer Polymers 0.000 description 2
229940048914 protamine Drugs 0.000 description 2
239000013049 sediment Substances 0.000 description 2
239000011734 sodium Substances 0.000 description 2
JHJLBTNAGRQEKS-UHFFFAOYSA-M sodium bromide Chemical compound [Na+].[Br-] JHJLBTNAGRQEKS-UHFFFAOYSA-M 0.000 description 2
239000007787 solid Substances 0.000 description 2
230000000087 stabilizing effect Effects 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
230000001026 thromboplastic effect Effects 0.000 description 2
229920000936 Agarose Polymers 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
206010053567 Coagulopathies Diseases 0.000 description 1
108010014173 Factor X Proteins 0.000 description 1
108010074860 Factor Xa Proteins 0.000 description 1
208000032843 Hemorrhage Diseases 0.000 description 1
241000282412 Homo Species 0.000 description 1
102000004895 Lipoproteins Human genes 0.000 description 1
108090001030 Lipoproteins Proteins 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
229920002684 Sepharose Polymers 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
108090000190 Thrombin Proteins 0.000 description 1
229930003448 Vitamin K Natural products 0.000 description 1
108010063628 acarboxyprothrombin Proteins 0.000 description 1
230000001133 acceleration Effects 0.000 description 1
239000013543 active substance Substances 0.000 description 1
125000001931 aliphatic group Chemical group 0.000 description 1
239000012670 alkaline solution Substances 0.000 description 1
150000005215 alkyl ethers Chemical class 0.000 description 1
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
239000000729 antidote Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
230000000740 bleeding effect Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
229940019700 blood coagulation factors Drugs 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
239000012928 buffer substance Substances 0.000 description 1
108090001015 cancer procoagulant Proteins 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
239000007795 chemical reaction product Substances 0.000 description 1
230000009852 coagulant defect Effects 0.000 description 1
230000000536 complexating effect Effects 0.000 description 1
208000019060 congenital factor VII deficiency Diseases 0.000 description 1
208000019059 congenital factor X deficiency Diseases 0.000 description 1
238000001816 cooling Methods 0.000 description 1
238000012937 correction Methods 0.000 description 1
229960000956 coumarin Drugs 0.000 description 1
235000001671 coumarin Nutrition 0.000 description 1
239000012043 crude product Substances 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
238000001035 drying Methods 0.000 description 1
239000003792 electrolyte Substances 0.000 description 1
230000005966 endogenous activation Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
229940012426 factor x Drugs 0.000 description 1
238000001914 filtration Methods 0.000 description 1
238000002523 gelfiltration Methods 0.000 description 1
150000004820 halides Chemical class 0.000 description 1
-1 heparin Chemical class 0.000 description 1
239000000815 hypotonic solution Substances 0.000 description 1
238000011534 incubation Methods 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
238000002642 intravenous therapy Methods 0.000 description 1
239000003456 ion exchange resin Substances 0.000 description 1
229920003303 ion-exchange polymer Polymers 0.000 description 1
244000005700 microbiome Species 0.000 description 1
235000010755 mineral Nutrition 0.000 description 1
239000011707 mineral Substances 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
239000012074 organic phase Substances 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
230000037361 pathway Effects 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
239000012071 phase Substances 0.000 description 1
SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
238000012545 processing Methods 0.000 description 1
238000004393 prognosis Methods 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
229950008679 protamine sulfate Drugs 0.000 description 1
235000004252 protein component Nutrition 0.000 description 1
239000002994 raw material Substances 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
239000013557 residual solvent Substances 0.000 description 1
238000000926 separation method Methods 0.000 description 1
159000000000 sodium salts Chemical class 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
239000007858 starting material Substances 0.000 description 1
238000011146 sterile filtration Methods 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
238000004659 sterilization and disinfection Methods 0.000 description 1
238000003756 stirring Methods 0.000 description 1
238000003860 storage Methods 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
229910021653 sulphate ion Inorganic materials 0.000 description 1
239000010414 supernatant solution Substances 0.000 description 1
238000012360 testing method Methods 0.000 description 1
229960004072 thrombin Drugs 0.000 description 1
230000001960 triggered effect Effects 0.000 description 1
238000005199 ultracentrifugation Methods 0.000 description 1
239000002821 viper venom Substances 0.000 description 1
235000019168 vitamin K Nutrition 0.000 description 1
239000011712 vitamin K Substances 0.000 description 1
150000003721 vitamin K derivatives Chemical class 0.000 description 1
229940046010 vitamin k Drugs 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/647—Blood coagulation factors not provided for in a preceding group or according to more than one of the proceeding groups
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/827—Proteins from mammals or birds
- Y10S530/85—Reproductive organs or embryos
- Y10S530/851—Placenta; amniotic fluid

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Zoology (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Biomedical Technology (AREA)
Genetics & Genomics (AREA)
Bioinformatics & Cheminformatics (AREA)
Hematology (AREA)
Biotechnology (AREA)
Cell Biology (AREA)
Developmental Biology & Embryology (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Wood Science & Technology (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Reproductive Health (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Virology (AREA)
Pregnancy & Childbirth (AREA)
Epidemiology (AREA)
Toxicology (AREA)
Gastroenterology & Hepatology (AREA)
General Engineering & Computer Science (AREA)
Biophysics (AREA)
Immunology (AREA)
Microbiology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Diabetes (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Peptides Or Proteins (AREA)

NO763776A 1975-11-07 1976-11-05 NO763776L (da)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DE2550011A DE2550011C2 (de)	1975-11-07	1975-11-07	Verfahren zur Herstellung eines antihämophilen Mittels

Publications (1)

Publication Number	Publication Date
NO763776L true NO763776L (da)	1977-05-10

Family

ID=5961172

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO763776A NO763776L (da)	1975-11-07	1976-11-05

Country Status (20)

Country	Link
US (1)	US4067964A (da)
JP (1)	JPS6029362B2 (da)
AT (1)	AT358737B (da)
AU (1)	AU500621B2 (da)
BE (1)	BE848111A (da)
CA (1)	CA1077393A (da)
CH (1)	CH630805A5 (da)
DE (1)	DE2550011C2 (da)
DK (1)	DK502176A (da)
ES (1)	ES452923A1 (da)
FI (1)	FI763165A7 (da)
FR (1)	FR2330408A1 (da)
GB (1)	GB1563009A (da)
IL (1)	IL50847A (da)
IT (1)	IT1063617B (da)
LU (1)	LU76145A1 (da)
NL (1)	NL7612139A (da)
NO (1)	NO763776L (da)
SE (1)	SE7612396L (da)
ZA (1)	ZA766647B (da)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0044343B1 (en) *	1980-01-28	1984-08-22	Baxter Travenol Laboratories, Inc.	Prothrombin-containing therapeutic compositions and methods of producing enzymatically active blood clotting factors from prothrombin-containing blood fractions
US4459288A (en) *	1981-05-11	1984-07-10	Baxter Travenol Laboratories, Inc.	Therapeutic blood clotting factor compositions and their use
DE3625090A1 (de) *	1986-07-24	1988-01-28	Behringwerke Ag	Mittel zur therapie faktor viii-resistenter haemophilie a und verfahren zu seiner herstellung
CA1339946C (en) *	1987-03-31	1998-07-07	Michael J. Griffith	Ultrapurification process for polypeptides
JP2931319B2 (ja) *	1989-03-29	1999-08-09	吉富製薬株式会社	血液凝固第▲ｖｉｉｉ▼因子の製造法
JP3180824B2 (ja) *	1991-08-30	2001-06-25	シスメックス株式会社	血液凝固試薬
KR20030088430A (ko) *	2001-02-05	2003-11-19	노보 노르디스크 헬스 케어 악티엔게젤샤프트	인자 ⅶ 폴리펩티드 및 인자 ⅸ 폴리펩티드의 조합 사용

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3862002A (en) *	1962-05-08	1975-01-21	Sanfar Lab Inc	Production of physiologically active placental substances
BE713764A (da) *	1967-05-01	1968-09-16	Baxter Travenol Lab
BE787961A (fr) *	1971-08-24	1973-02-26	Behringwerke Ag	Procede d'isolement d'une matiere thromboplastique et medicament contenant ladite matiere
DE2262520C3 (de) *	1972-12-20	1987-02-12	Miles Laboratories, Inc., Elkhart, Ind.	Verfahren zur Herstellung eines lyophilisierten, lagerfähigen Konzentrats aus menschlichem Plasma

1975
- 1975-11-07 DE DE2550011A patent/DE2550011C2/de not_active Expired
1976
- 1976-11-02 NL NL7612139A patent/NL7612139A/xx not_active Application Discontinuation
- 1976-11-02 ES ES452923A patent/ES452923A1/es not_active Expired
- 1976-11-04 AT AT819476A patent/AT358737B/de not_active IP Right Cessation
- 1976-11-04 IL IL50847A patent/IL50847A/xx unknown
- 1976-11-04 CH CH1392076A patent/CH630805A5/de not_active IP Right Cessation
- 1976-11-04 FI FI763165A patent/FI763165A7/fi not_active Application Discontinuation
- 1976-11-05 SE SE7612396A patent/SE7612396L/xx unknown
- 1976-11-05 DK DK502176A patent/DK502176A/da unknown
- 1976-11-05 IT IT29084/76A patent/IT1063617B/it active
- 1976-11-05 US US05/739,278 patent/US4067964A/en not_active Expired - Lifetime
- 1976-11-05 AU AU19341/76A patent/AU500621B2/en not_active Expired
- 1976-11-05 CA CA265,060A patent/CA1077393A/en not_active Expired
- 1976-11-05 ZA ZA766647A patent/ZA766647B/xx unknown
- 1976-11-05 LU LU76145A patent/LU76145A1/xx unknown
- 1976-11-05 NO NO763776A patent/NO763776L/no unknown
- 1976-11-06 JP JP51132782A patent/JPS6029362B2/ja not_active Expired
- 1976-11-08 BE BE172170A patent/BE848111A/xx not_active IP Right Cessation
- 1976-11-08 GB GB46384/76A patent/GB1563009A/en not_active Expired
- 1976-11-08 FR FR7633603A patent/FR2330408A1/fr active Granted

Also Published As

Publication number	Publication date
FR2330408A1 (fr)	1977-06-03
IL50847A0 (en)	1977-01-31
AT358737B (de)	1980-09-25
FI763165A7 (da)	1977-05-08
CA1077393A (en)	1980-05-13
SE7612396L (sv)	1977-05-08
JPS6029362B2 (ja)	1985-07-10
AU500621B2 (en)	1979-05-24
ZA766647B (en)	1977-10-26
IL50847A (en)	1980-01-31
US4067964A (en)	1978-01-10
ATA819476A (de)	1980-02-15
DE2550011A1 (de)	1977-05-12
JPS5257310A (en)	1977-05-11
GB1563009A (en)	1980-03-19
AU1934176A (en)	1978-05-11
CH630805A5 (de)	1982-07-15
BE848111A (fr)	1977-05-09
ES452923A1 (es)	1977-11-16
DE2550011C2 (de)	1982-11-25
DK502176A (da)	1977-05-08
FR2330408B1 (da)	1980-03-14
LU76145A1 (da)	1977-06-03
NL7612139A (nl)	1977-05-10
IT1063617B (it)	1985-02-11

Publication	Publication Date	Title
Hovig	1963	Aggregation of rabbit blood platelets produced in vitro by saline “extract” of tendons
Margolis	1957	Initiation of blood coagulation by glass and related surfaces
US3682881A (en)	1972-08-08	Fractionation of plasma using glycine and polyethylene glycol
DK151932B (da)	1988-01-18	Fremgangsmaade til fremstilling af et blodstoerkningsfremmende praeparat af menneskeligt blodplasma
O'brien	1956	The similarity of the action of phosphatidyl-ethanolamine and platelets in blood coagulation
NO142381B (no)	1980-05-05	Fremgangsmaate for fremstilling av den antihemofile faktor
JPS62174023A (ja)	1987-07-30	抗血液凝固物質、その製法及びそれを有効成分とする抗血液凝固剤
Rapaport et al.	1967	The blood clotting properties of rabbit peritoneal leukocytes in vitro
Borsook et al.	1969	Studies on erythropoiesis II. A method of segregating immature from mature adult rabbit erythroblasts
JPS644621B2 (da)	1989-01-26
US4870166A (en)	1989-09-26	Process for preparing high-purity dematan sulphate, and pharmaceutical compositions which contain it
JPH0348888B2 (da)	1991-07-25
NO138145B (no)	1978-04-03	Fremgangsmaate for fremstilling av et enzympreparat
NO763776L (da)	1977-05-10
JPH03503534A (ja)	1991-08-08	トロンボプラスチン試薬を製造するための改良された抽出方法
CA1293941C (en)	1992-01-07	Method for preparing antihemophilic factor (ahf) by cold precipitation and for improving solubility of recovered ahf product
EP0303236B1 (en)	1992-11-11	Lignosulfonate based pharmacologic agent with anti-thrombotic activity
US4115551A (en)	1978-09-19	Compounds of the plasminogen type and method for obtaining such compounds from placental pulps
van Iwaarden et al.	1995	A novel procedure for the rapid isolation of surfactant protein A with retention of its alveolar-macrophage-stimulating properties
Bloom et al.	1972	Factor VIII (antihaemophilic factor) in tissues detected by antibody neutralization
EP0052874A1 (en)	1982-06-02	Method for synthesizing procoagulant factor VIII activity
Casillas et al.	1969	Chromatographic behaviour of clotting factors
Seegers et al.	1954	Activation of purified prothrombin with platelets combined with various crude biochemical preparations
Fujimoto	1918	Studies on the antitrypsin of serum
FI87044B (fi)	1992-08-14	Foerfarande foer framstaellning av ett medel med vilket man kan behandla hemofili a, som aer resistent mot faktor viii.